Formula Ia Antiviral Efficacy Chloroquine Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating viral infections caused by Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxovirus, Pneumoviridae, and Paramyxoviridae are limited due to a lack of effective vaccines or post-exposure treatments, often relying on supportive therapy, and existing antiviral compounds like the compound of Formula Ia face efficacy reduction when co-administered with chloroquine or its analogs.
Innovation Solution
Administering a therapeutically effective amount of the compound of Formula I, Formula Ia, or Formula Ib, or their pharmaceutically acceptable salts, while ensuring the patient has not been treated with chloroquine or its analogs, to optimize plasma or blood concentration and maintain antiviral efficacy, and adjusting doses based on chloroquine presence to prevent efficacy reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If chloroquine or its analogs are co-administered with the compound of Formula Ia, then broad-spectrum antiviral coverage is achieved, but the antiviral activity of the compound of Formula Ia is decreased or attenuated
Solution Approach 1:
The patent extracts and eliminates chloroquine from the combination therapy regimen when treating viral infections with the compound of Formula Ia. By removing chloroquine from the treatment protocol, the patent prevents the attenuation of antiviral activity while maintaining the use of the compound of Formula Ia at standard doses, thereby resolving the contradiction between broad-spectrum coverage and reliable antiviral efficacy.
2Reliability
If the dose of the compound of Formula Ia is increased to overcome chloroquine interference, then antiviral efficacy is maintained, but the complexity of dosage management increases
Solution Approach 1:
Rather than increasing the dose of the compound of Formula Ia to overcome chloroquine interference, the patent takes out chloroquine from the combination therapy entirely. This approach maintains antiviral efficacy at standard doses of the compound of Formula Ia while avoiding the complexity of adjusted dosage regimens and monitoring requirements.
Data Source
AI summary
Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.